Deuterated etifoxine is under clinical development by GABA Therapeutics and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Deuterated etifoxine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deuterated etifoxine overview

Deuterated etifoxine is under development for the treatment of neuropathic and inflammatory pain, multiple sclerosis, epilepsy, generalized anxiety disorder, social anxiety disorder (SAD), post-traumatic stress disorder (PTSD), major depressive disorder (MDD), treatment resistant depression (TRD), post partum depression (PPD), essential tremor, depression, Alzheimer’s disease, stroke, traumatic brain injury, nerve/spinal cord injury and retinal/macular degeneration. Deuterated etifoxine is a version of racemic etifoxine. It is administered through oral route. It is developed based on allosteric modulation technology. It acts by targeting GABAA receptors and TSPO. D-etifoxine is a new chemical entity (NCE).

It was also under development for the treatment of autism spectrum disorders(ASD) and pediatric epilepsy.

GABA Therapeutics overview

Gaba Therapeutics is a therapeutic company that develops anxiety medications. The company is headquartered in Newport Beach, California, the US

For a complete picture of Deuterated etifoxine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.